How CBD Could Alleviate Reproductive Health Issues & Why Investors Should Take Note

Cannabidiol, better known as CBD, has a growing body of evidence suggesting it could help with everything from seizures to inflammation. While the research remains early-stage, the widespread availability of CBD and its established safety profile means anyone can experiment and see what works with limited side effects.

Let’s look at how BYND Cannasoft Corp. (NASDAQ: BCAN) (CSE: BYND) aims to reshape female reproductive health with its upcoming, patent-pending EZ-G product.

A Massive Market Opportunity

Many CBD companies sell supplements or topicals to treat pain, inflammation, and other generalized problems. While these are multi-billion dollar markets, there’s lots of competition and few barriers to entry. As a result, investors may want to seek out more niche use cases where companies can build a valuable presence.

BYND Cannasoft will target women’s reproductive health with its upcoming EZ-G device. While many people use CBD lotion and suppositories, few products are purpose-built to address reproductive health issues. The EZ-G device will deliver a precise CBD oil dose into vaginal tissues to address various reproductive health issues.

In particular, the device could help address conditions like:

• Endometriosis affects up to 15% of women, causing severe pain and inflammation in the pelvic region.
• Dyspareunia, or painful sex, affects 10% to 20% of women and arises from several possible underlying causes.
• Pelvic Floor Dysfunction affects one-in-three women and occurs when the pelvic floor is hypertonic, making any penetration painful.
• Cramps affect 80% of women and often occur during menstruation.
• Menopause eventually affects every woman and causes many unpleasant symptoms, including vaginal dryness and hot flashes.

In addition to potentially treating these highly prevalent problems, CBD could help increase pleasure from sex by promoting relaxation and increasing blood flow. According to one study of 5,398 U.S. residents, 9.3% took CBD for sex, and 68% of those individuals said their orgasms were more intense after taking a supplement.

How to Invest in Solutions

The 2018 Farm Bill removed hemp from the legal definition of marijuana in the Controlled Substances Act, making some hemp-derived products with less than 0.3% THC federally legal. Since then, companies have been legally permitted to develop and sell hemp-based CBD products without any concerns about regulatory red tape.

BYND Cannasoft Corp. (NASDAQ: BCAN) (CSE: BYND) acquired the patent-pending intellectual property for the EZ-G device in September 2022. The smart vibrator device will feature proprietary software that regulates the flow of low-concentration CBD lubricant (oil) into the soft tissues of the female reproductive system.

[embedded content]

By delivering precise concentrations of CBD directly to vaginal tissue, the EZ-G will help maximize the regional bioavailability of CBD. CBD is already known to help with inflammation and pain by acting on the body’s cannabinoid receptors. Emerging research further suggests it could help with anxiety, blood flow, and other issues.

In October, the company entered into a consulting service agreement with Matrix Medika, a specialist helping companies obtain regulatory approval for development-stage medical devices. The company aims to get European and United States regulatory approval for the EZ-G device as part of its B2B and B2C go-to-market plans.

Looking Ahead

BYND Cannasoft Corp. (NASDAQ: BCAN) (CSE: BYND) offers a unique opportunity to invest in a unique but massive corner of the CBD market. By delivering CBD directly to reproductive issues, the company’s upcoming, patent-pending EZ-G device could offer relief from many different reproductive health conditions – and unlock significant shareholder value in the meantime.

For more information, visit the company’s website or complete the form below to download the investors presentation.

Disclaimer

This website contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from those shown on the website including those factors discussed in filings made by us with the Canadian or US securities regulatory authorities. Should one or more of these risks and uncertainties, such as currency and interest rate fluctuations, increased competition, and general economic and market factors, occur or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements. The medical cannabis license is subject to the provisions of the medical cannabis unit in the ministry of health in Israel and there is no guarantee the company will succeed in getting it. The company intends to obtain approval for the EZ-G patent within the accepted timescales. Additional regulatory standards may be required, including FDA approval or any other approval for the purpose of manufacturing, marketing, and selling the device under therapeutic indications. There is no certainty that the aforementioned approvals will be received and all the information below is forward-looking. The model of the device that appears in the video is not a working device and is a visualization as a concept model only and there is no certainty that it will be compatible with the prototype of the product when it is made in the future.

The above article is sponsored content. CFN Media has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cfnmedia.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.